A Day Up For Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ) jumped higher at $0.2, a gain of 48.1%. The stock got featured on our News Catalysts scanner on Wed, Jan 22, 2025 at 10:30 AM in the 'PUBLIC OFFERING' category. From Fri, Jan 10, 2025, the stock recorded 37.50% Up Days and 33.33% Green Days
About Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ)
ContraVir Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. The company focuses on developing two novel oral compounds to treat HBV infection. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. TXL is a nucleotide pro-drug of tenofovir that inhibits hepatitis B viral replication and targets the liver, the reservoir for the hepatitis B virus.
Top 10 Gainers:
- Dogwood Therapeutics Inc. (DWTX:NASDAQ), 376.79%
- Diginex Limited (DGNX:NASDAQ), 70%
- Vince Holding Corp. (VNCE:NYSE), 65.96%
- TransCode Therapeutics Inc. (RNAZ:NASDAQ), 57.14%
- CTRL Group Limited (MCTR:NASDAQ), 56.81%
- Evaxion Biotech A/S (EVAX:NASDAQ), 52.94%
- Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ), 48.15%
- N2OFF Inc. (NITO:NASDAQ), 45.34%
- Lightbridge Corporation (LTBR:NASDAQ), 41.11%
- LatAmGrowth SPAC (LATG:NASDAQ), 40%